The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Baxter is recalling one lot of Heparin Sodium in 0.9% Sodium Chloride Injection due to the potential for elevated endotoxin levels based on issues related to the bacterial endotoxin test specific to lot number N008235.

Use of heparin with higher than acceptable endotoxin levels may lead to significant adverse health consequences ranging from febrile reactions to toxic shock, multi-organ failure and death.

This issue affects one lot of product code that was distributed between March 12, 2023, and August 24, 2023, to healthcare facilities, wholesalers and distributors in the United States.

To date, Baxter has not received any reports of adverse events related to this issue.

Heparin Sodium in Sodium Chloride Injection is indicated as an anticoagulant to maintain catheter patency.

- Customers with questions regarding this recall should contact Baxter Healthcare Center for Service at (888)-229-0001.
- Any product quality complaints or adverse events experienced with the use of these products may be reported using one of the following options.

Contacting Baxter Product Surveillance at the Baxter product feedback portal at https://productfeedback.baxter.comExternal Link Disclaimer or emailing Baxter at corporate_product_complaints_round_lake@baxter.com